LRRK2 and Parkinson disease: The dosage sensitivity to wild-type Lrrk that we demonstrate in vivo (Fig 1) and model biochemically (Fig 6) is consistent with recovery of noncoding Parkinson disease risk variants at the LRRK2 locus, which presumably predispose to disease by modulating LRRK2 expression [11].